| 38.72 -0.89 (-2.25%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 60.42 | 1-year : | 70.61 |
| Resists | First : | 51.73 | Second : | 60.46 |
| Pivot price | 46.41  |
|||
| Supports | First : | 37.61 | Second : | 31.29 |
| MAs | MA(5) : | 39.56 |
MA(20) : | 48.15 |
| MA(100) : | 46.54 |
MA(250) : | 31.91 |
|
| MACD | MACD : | -3.8 |
Signal : | -2.5 |
| %K %D | K(14,3) : | 7 |
D(3) : | 6.9 |
| RSI | RSI(14): 27.8 |
|||
| 52-week | High : | 62.2 | Low : | 12.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BHVN ] has closed above bottom band by 16.8%. Bollinger Bands are 137.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 40.74 - 40.96 | 40.96 - 41.15 |
| Low: | 37.7 - 38.01 | 38.01 - 38.26 |
| Close: | 38.26 - 38.72 | 38.72 - 39.1 |
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Thu, 18 Apr 2024
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares - Quantisnow
Wed, 17 Apr 2024
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN): Is Breakeven Near? - Yahoo Movies UK
Tue, 16 Apr 2024
BHVN June 21st Options Begin Trading - Nasdaq
Sun, 31 Mar 2024
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising - Yahoo Movies UK
Wed, 04 Oct 2023
Biohaven (BHVN) prices its $225m public offering of common shares - Leaprate Forex Trading News
Mon, 03 Oct 2022
Pfizer Completes Acquisition of Biohaven Pharmaceuticals - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 82 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 89.7 (%) |
| Shares Short | 8,570 (K) |
| Shares Short P.Month | 7,730 (K) |
| EPS | -5.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46.4 % |
| Return on Equity (ttm) | -84.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -332 (M) |
| Levered Free Cash Flow | -214 (M) |
| PE Ratio | -6.76 |
| PEG Ratio | 0 |
| Price to Book value | 7.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|